Total Valuation
Aprogen Biologics has a market cap or net worth of ₩23.88B. The enterprise value is $294.17K.
Market Cap₩23.88B
Enterprise Value$294.17K
Share Statistics
Aprogen Biologics has 16,261,204 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding16,261,204
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Aprogen Biologics’s return on equity (ROE) is -0.82 and return on invested capital (ROIC) is -23.13%.
Return on Equity (ROE)-0.82
Return on Assets (ROA)-0.29
Return on Invested Capital (ROIC)-23.13%
Return on Capital Employed (ROCE)-0.34
Revenue Per Employee194.23M
Profits Per Employee-451.81M
Employee Count377
Asset Turnover0.12
Inventory Turnover1.97
Valuation Ratios
The current PE Ratio of Aprogen Biologics is ―. Aprogen Biologics’s PEG ratio is -0.19.
PE Ratio―
PS Ratio1.41
PB Ratio0.50
Price to Fair Value0.50
Price to FCF-2.15
Price to Operating Cash Flow-0.68
PEG Ratio-0.19
Income Statement
In the last 12 months, Aprogen Biologics had revenue of 73.23B and earned -170.33B in profits. Earnings per share was -12.92K.
Revenue73.23B
Gross Profit-28.42B
Operating Income-122.89B
Pretax Income-169.38B
Net Income-170.33B
EBITDA-103.70B
Earnings Per Share (EPS)-12.92K
Cash Flow
In the last 12 months, operating cash flow was -32.32B and capital expenditures -3.83B, giving a free cash flow of -36.15B billion.
Operating Cash Flow-32.32B
Free Cash Flow-36.15B
Free Cash Flow per Share-2.22K
Dividends & Yields
Aprogen Biologics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.11
52-Week Price Change-82.79%
50-Day Moving Average1.87K
200-Day Moving Average4.07K
Relative Strength Index (RSI)38.18
Average Volume (3m)525.55K
Important Dates
Aprogen Biologics upcoming earnings date is Aug 19, 2026, TBA (Confirmed).
Last Earnings DateMay 14, 2026
Next Earnings DateAug 19, 2026
Ex-Dividend Date―
Financial Position
Aprogen Biologics as a current ratio of 0.67, with Debt / Equity ratio of 108.55%
Current Ratio0.67
Quick Ratio0.45
Debt to Market Cap2.02
Net Debt to EBITDA-1.94
Interest Coverage Ratio-11.49
Taxes
In the past 12 months, Aprogen Biologics has paid -1.08B in taxes.
Income Tax-1.08B
Effective Tax Rate<0.01
Enterprise Valuation
Aprogen Biologics EV to EBITDA ratio is -2.93, with an EV/FCF ratio of -6.35.
EV to Sales4.15
EV to EBITDA-2.93
EV to Free Cash Flow-6.35
EV to Operating Cash Flow-7.95
Balance Sheet
Aprogen Biologics has ₩22.70B in cash and marketable securities with ₩210.84B in debt, giving a net cash position of -₩188.14B billion.
Cash & Marketable Securities₩22.70B
Total Debt₩210.84B
Net Cash-₩188.14B
Net Cash Per Share-₩11.57K
Tangible Book Value Per Share₩20.84K
Margins
Gross margin is -27.08%, with operating margin of -167.82%, and net profit margin of -232.61%.
Gross Margin-27.08%
Operating Margin-167.82%
Pretax Margin-231.31%
Net Profit Margin-232.61%
EBITDA Margin-141.62%
EBIT Margin-167.82%
Analyst Forecast
The average price target for Aprogen Biologics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast26.13%
EPS Growth Forecast58.75%